{"id":210010,"date":"2010-01-21T18:45:19","date_gmt":"2010-01-21T23:45:19","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=59619"},"modified":"2010-01-21T18:45:19","modified_gmt":"2010-01-21T23:45:19","slug":"occulogix-raises-1-7m-in-round-targeting-5m","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/210010","title":{"rendered":"OccuLogix Raises $1.7M in Round Targeting $5M"},"content":{"rendered":"\n
Life Sciences<\/a>, Venture Capital<\/a>, Biomedical Diagnostics<\/a><\/div>\n

\t\tBruce V. Bigelow wrote:<\/strong><\/p>\n

OccuLogix, a biotech startup founded near Toronto, Canada, in 1996 to develop ophthalmic treatments for age-related macular degeneration and glaucoma, apparently has relocated in San Diego, according to an SEC filing. In its Form D<\/a> filed today, OccuLogix discloses that it has raised more than $1.7 million from investors in a round that intends to raise $5 million.<\/p>\n

The company is listed as a Toronto-area company on LinkedIn<\/a> and Hoover’s<\/a>. But OccuLogix, which is now doing business as TearLab, lists a San Diego address in its SEC filing and on its website<\/a>. The company describes itself as an “in-vitro diagnostics company developing and commercializing novel, lab-on-a-chip technologies that enable eye care practitioners to test for highly sensitive and specific biomarkers in tears at the point-of-care.”<\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

\t \t\t

\n

\n\"\"<\/a>
\n\"\"<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Life Sciences, Venture Capital, Biomedical Diagnostics Bruce V. Bigelow wrote: OccuLogix, a biotech startup founded near Toronto, Canada, in 1996 to develop ophthalmic treatments for age-related macular degeneration and glaucoma, apparently has relocated in San Diego, according to an SEC filing. In its Form D filed today, OccuLogix discloses that it has raised more than […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-210010","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/210010","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=210010"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/210010\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=210010"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=210010"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=210010"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}